GI Innovation (A358570) Stock Overview
A bio-venture company, engages in the research and development of protein new drugs. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
A358570 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
GI Innovation, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩16,380.00 |
| 52 Week High | ₩24,900.00 |
| 52 Week Low | ₩7,836.36 |
| Beta | 0.42 |
| 1 Month Change | -13.56% |
| 3 Month Change | -14.24% |
| 1 Year Change | 88.08% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 77.96% |
Recent News & Updates
Health Check: How Prudently Does GI Innovation (KOSDAQ:358570) Use Debt?
Oct 15
Does GI Innovation (KOSDAQ:358570) Have A Healthy Balance Sheet?
Jun 26Shareholder Returns
| A358570 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -7.1% | 3.8% | 7.0% |
| 1Y | 88.1% | 46.0% | 75.4% |
Return vs Industry: A358570 exceeded the KR Biotechs industry which returned 46% over the past year.
Return vs Market: A358570 exceeded the KR Market which returned 75.4% over the past year.
Price Volatility
| A358570 volatility | |
|---|---|
| A358570 Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.9% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A358570's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A358570's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Jun Ho Hong | www.gi-innovation.com |
GI Innovation, Inc., a bio-venture company, engages in the research and development of protein new drugs. The company is developing GI-101, an immune anticancer drug with novel dual fusion protein in Phase I/II clinical trial; and GI-301, an IgE-mediated allergy treatment designed as a fusion protein that is in Phase I clinical trial. It is also developing GI-10N, an immuno-oncology drug; GI-30N, a drug for allergic and fibrotic diseases; and GI-20N, a drug for metabolic diseases.
GI Innovation, Inc. Fundamentals Summary
| A358570 fundamental statistics | |
|---|---|
| Market cap | ₩1.08t |
| Earnings (TTM) | -₩51.99b |
| Revenue (TTM) | ₩338.09m |
Is A358570 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A358570 income statement (TTM) | |
|---|---|
| Revenue | ₩338.09m |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩338.09m |
| Other Expenses | ₩52.33b |
| Earnings | -₩51.99b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -814.21 |
| Gross Margin | 100.00% |
| Net Profit Margin | -15,376.98% |
| Debt/Equity Ratio | 3.5% |
How did A358570 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/07 09:56 |
| End of Day Share Price | 2026/01/07 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GI Innovation, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.